BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Javle MM, Oh DY, Ikeda M, Yong WP, Hsu K, Lindmark B, McIntyre N, Firth C. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO Open 2021;7:100314. [PMID: 34922298 DOI: 10.1016/j.esmoop.2021.100314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zeng W, Mao R, Zhang Z, Chen X. Combination Therapies for Advanced Biliary Tract Cancer. J Clin Transl Hepatol 2023;11:490-501. [PMID: 36643047 DOI: 10.14218/JCTH.2022.00277] [Reference Citation Analysis]
2 Uson Junior PLS, Bearss J, Babiker HM, Borad MJ. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials. Expert Opin Investig Drugs 2023;:1-7. [PMID: 36714945 DOI: 10.1080/13543784.2023.2173064] [Reference Citation Analysis]
3 Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)03296-2. [PMID: 36400328 DOI: 10.1016/j.jhep.2022.11.005] [Reference Citation Analysis]
4 Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers 2022;8:69. [DOI: 10.1038/s41572-022-00398-y] [Reference Citation Analysis]